12 November 2025   Inventia Life Science's 3D bioprinted patient-derived cancer models has opened the door for Hunter Medical Research Institute to advance its drug repurposing program into Australian New Zealand clinical trials .   The drug in question, efavirenz, is known as an antiretroviral NNRTI (non‑nucleoside reverse transcriptase inhibitor) used for treating HIV. Its repurposing has the potential to improve the survival of patients with high-grade serous ovarian cance